Nivalis Therapeutics (NVLS) Priced

Developing a complementary small molecule therapy for cystic fibrosis.

Health Care - Biotechnology

IPO Performance
Latest Trade $2.79 0.00 (0.0%)
First Day Return 6.6%
Return from IPO -80.1%
 
Nivalis Therapeutics IPO News more
  • .
IPO Data
IPO File Date 05/13/2015
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.5
Deal Size ($mm) 77
 
IPO Data
IPO Date 06/16/2015
Offer Price $14.00
Price Range $13.00 - $15.00
Offer Shares (mm) 5.5
Deal Size ($mm) $77
 
Underwriters
more
Business Overview
Developing a complementary small molecule therapy for cystic fibrosis.
Developing a complementary small molecule therapy for cystic fibrosis.
more
Company Data
Headquarters Boulder, CO
Founded 2007
Employees 23
Website www.nivalis.com
 

Performance vs. IPO Index (IPOUSA)